Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease by Yuqi Qiu, Diane M. Jacobs, Karen Messer, David P. Salmon, Cheryl L. Wellington, Sophie Stukas, Carolyn Revta, James B. Brewer, Gabriel C. Léger, Brianna Askew, Lia Donahue, Stephen Kaplita, Vladimir Coric, Irfan A. Qureshi, Howard H. Feldman, The Alzheimer’s Disease Cooperative Study T2 Protect AD Study Group

Get full text